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ABSTRACT
Pasteurella multocida (P. multocida) serotype B is associated with hemorrhagic 
septicaemia (HS) disease endemic in Africa, India and Asian countries. It is causative 
agent o f thriftily significant disease in livestock. Hence, this study purposed and 
aimed to identify and express an immunogenic soluble protein o f P. multocida in 
efforts toward development of HS vaccine. Immunogenic soluble protein was 
identified as lipoprotein B (plpB) using electrospray mass spectrometry. The size o f 
expressed purified recombinant protein was approximately 39kDa. Immunogenicity 
study o f the recombinant protein plpB was carried out using 6  groups o f BALB/c 
mice. The groups were immunized with recombinant protein (Group 1), soluble 
recombinant protein (Group 2), insoluble recombinant protein (Group 3), vector 
(Group 4), soluble protein o f P. multocida (Group 5) and PBS (Group 6 ) respectively. 
Mice in group 4 and 6  showed signs and symptom of HS after challenge with the 
parental strain (p-value < 0.05). However, immunised mice with purified recombinant 
protein did not show signs and symptoms o f HS. Based on immunoblotting analysis, 
purified recombinant protein was significantly immunogenic (p-value < 0.05). 
Additionally, no inflammation was seen in the tissues o f organs from mice immunized 
with purified recombinant protein, which indicates that recombinant protein was 
100% protective towards P. multocida infection and eventually towards HS disease. 
Thus, this study shows that the recombinant protein lipoprotein B (plpB) is 
significantly immunogenic and could be a potential candidate in developing vaccine 
against HS.
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CHAPTER ONE 
INTRODUCTION
1.1 RESEARCH BACKGROUND
In 1887, Trevisan pristinely proposed and described genus Pasteurella. It is a 
group o f nonmotile, minute (0.7|im by 0.5|im) gram negative coccobacilli. It often 
exhibits a characteristic type o f bipolar staining (Albrecht et al., 1996). The first 
pathogen to be analyzed which is called Pasteurella septic was shown to cause 
hemorrhagic septicaemia (Bain et al., 1982) in cattle and sheep and fowl cholera in 
chickens (Curtis, 1979). Pasteur utilized it for his vaccination studies in 1880 
(Trevisan, 1887) and it is now called Pasteurella multocida (P. multocida). 
P. multocida is a heterogeneous species which can cause respiratory diseases in 
domestic and wild animals (Jubb et al, 1985).
P. multocida is named in honor o f Louis Pasteur who in a classic experiment 
in the early 1880s attenuated the agent and so produced the first deliberately 
developed a vaccine (Rimler, 2001). P. multocida has a pathogenic potential in 
vertebrate animals (Dziva et al., 2008). It is a commensal o f the upper respiratory tract 
of many animal species too. Then again, under inclining conditions the bacterium is 
the etiological operator of extensive variety o f monetarily weighty infections, 
incorporating fowl cholera in poultry, haemorrhagic septicaemia in dairy calves and 
bison, atrophic rhinitis in swine and sniffles in rabbits. The living being is moreover 
apperceived to be the contributory executor of Pasteurellosis in American cow, yak, 
deer, elephants, camels, stallions, moose and other savage creatures. Besides, 
P. multocida can cause a zoonotic infection in man. It is conventionally because of 
bites or scratches from pets such as cats and dogs (Hawkins, 1969).
P. multocida comprises o f five capsular type A, B, D, E, and F and there is 
association between the capsular type and illness (Carter, 1952; Boyce et al., 2000). 
Serotype A causes fowl cholera in avian species and enzootic bronchopneumonia or 
pneumonic pasteurellosis in bovine. In pigs, atrophic rhinitis plus pneumonia are 
related essentially by toxigenic strains o f serotype D and serotype A, respectively. 
P. multocida serotype B: 2, B: 2, 5 and B:5 cause hemorrhagic septicemia in dairy
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